Acetylcholinesterase Inhibitor
Pregnancy: Avoid — no data
Donepezil
Brand names: Aricept
Adult dose
Dose: Starting: 5 mg OD at night × 4 weeks, then 10 mg OD at night. Moderate-severe: may increase to 23 mg OD (specialist).
Route: Oral
Frequency: Once daily at bedtime
Max: 23 mg OD (specialist use); standard 10 mg OD
For Alzheimer's disease (mild-moderate-severe). Take at bedtime — anticholinergic side effects and insomnia if taken in the morning. NICE TA217: first-line for mild-moderate AD.
Paediatric dose
Route: N/A
Frequency: N/A
Max: Not licensed in children
Not applicable in paediatric patients
Dose adjustments
Renal
No dose adjustment required
Hepatic
Caution in hepatic impairment — reduce dose if significant
Clinical pearls
- NICE TA217: donepezil, rivastigmine, galantamine recommended for mild-moderate AD
- Bedtime dosing: reduces nausea and insomnia side effects — always prescribe at night
- Cholinergic bradycardia: check resting HR and ECG before starting — relevant for patients with sick sinus syndrome
- Nightmares: switch to morning dosing if persistent (trade-off with insomnia risk)
Contraindications
- Hypersensitivity to piperidine derivatives
Side effects
- Nausea/vomiting (common — take with food)
- Diarrhoea
- Insomnia (take at bedtime)
- Nightmares (often resolves)
- Bradycardia (check ECG in cardiac patients)
- Muscle cramps
- Syncope
- GI haemorrhage (ulcerogenic — use PPI if NSAIDs co-prescribed)
Interactions
- Beta-blockers — additive bradycardia
- Anticholinergic drugs — reduced donepezil efficacy (compete)
- NSAIDs — increased GI bleeding risk (both are ulcerogenic)
- QT-prolonging drugs — donepezil has mild QT risk
Monitoring
- Cognitive assessments (MMSE, MOCA at 3 and 6 months)
- Heart rate and ECG
- GI symptoms
- Weight and nutritional status
Reference: BNFc; BNF; NICE TA217; UK Dementia Prevention Commission. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Drugs
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS